BFM
PMVP icon

Boothbay Fund Management’s PMV Pharmaceuticals PMVP Stock Holding History

Boothbay Fund Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,100
Closed -$252K – 2578
2022
Q1 		$252K Buy
+12,100
New +$213K 0.01% 1736

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Boothbay Fund Management's PMVP Position: Q2 2026 in Review

Boothbay Fund Management held its PMV Pharmaceuticals (PMVP) position steady in Q2 2026 at 27,126 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2125.

Boothbay Fund Management first reported a position in PMVP in Q3 2025 and has held it in 4 quarters since. The position peaked at $282K in Q3 2025. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Boothbay Fund Management held 27,126 shares of PMV Pharmaceuticals worth $36.3K as of Q2 2026.
  • Boothbay Fund Management left its PMV Pharmaceuticals share count unchanged in Q2 2026.
  • PMV Pharmaceuticals made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2125 holding.
  • Boothbay Fund Management first reported a position in PMV Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Boothbay Fund Management's PMV Pharmaceuticals position peaked at $282K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.